Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based study

被引:10
|
作者
Eroglu, Talip E. [1 ,2 ,3 ]
Jia, Lixia [1 ]
Blom, Marieke T. [1 ]
Verkerk, Arie O. [1 ,4 ]
Devalla, Harsha D. [1 ,4 ]
Boink, Gerard J. J. [1 ,4 ]
Souverein, Patrick C. [2 ]
de Boer, Anthonius [2 ]
Tan, Hanno L. [1 ,5 ]
机构
[1] Univ Amsterdam, Heart Ctr, Dept Cardiol, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[3] Copenhagen Univ Hosp Herlev & Gentofte, Dept Cardiol, Hellerup, Denmark
[4] Univ Amsterdam, Dept Med Biol, Amsterdam UMC, Amsterdam, Netherlands
[5] Netherlands Heart Inst, Utrecht, Netherlands
关键词
ESCAPE‐ NET; K-ATP channelssulfonylurea; sudden cardiac arrest;
D O I
10.1111/bcp.14774
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Out-of-hospital cardiac arrest (OHCA) mostly results from ventricular tachycardia/ventricular fibrillation (VT/VF), often triggered by acute myocardial infarction (AMI). Sulfonylurea (SU) antidiabetics can block myocardial ATP-regulated K+ channels (K-ATP channels), activated during AMI, thereby modulating action potential duration (APD). We studied whether SU drugs impact on OHCA risk, and whether these effects are related to APD changes. Methods We conducted a population-based case-control study in 219 VT/VF-documented OHCA cases with diabetes and 697 non-OHCA controls with diabetes. We studied the association of SU drugs (alone or in combination with metformin) with OHCA risk compared to metformin monotherapy, and of individual SU drugs compared to glimepiride, using multivariable logistic regression analysis. We studied the effects of these drugs on APD during simulated ischaemia using patch-clamp studies in human induced pluripotent stem cell-derived cardiomyocytes. Results Compared to metformin, use of SU drugs alone or in combination with metformin was associated with reduced OHCA risk (ORSUdrugs-alone 0.6 [95% CI 0.4-0.9], ORSUdrugs + metformin 0.6 [95% CI 0.4-0.9]). We found no differences in OHCA risk between SU drug users who suffered OHCA inside or outside the context of AMI. Reduction of OHCA risk compared to glimepiride was found with gliclazide (ORadj 0.5 [95% CI 0.3-0.9]), but not glibenclamide (ORadj 1.3 [95% CI 0.6-2.7]); for tolbutamide, the association with reduced OHCA risk just failed to reach statistical significance (ORadj 0.6 [95% CI 0.3-1.002]). Glibenclamide attenuated simulated ischaemia-induced APD shortening, while the other SU drugs had no effect. Conclusions SU drugs were associated with reduced OHCA risk compared to metformin monotherapy, with gliclazide having a lower risk than glimepiride. The differential effects of SU drugs are not explained by differential effects on APD.
引用
收藏
页码:3588 / 3598
页数:11
相关论文
共 50 条
  • [1] Acetylsalicylic acid use is associated with reduced risk of out-of-hospital cardiac arrest in the general population: Real-world data from a population-based study
    Eroglu, Talip E.
    Blom, Marieke T.
    Souverein, Patrick C.
    Yasmina, Alfi
    de Boer, Anthonius
    Tan, Hanno L.
    PLOS ONE, 2022, 17 (06):
  • [2] Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study
    Eroglu, Talip E.
    Blom, Marieke T.
    Souverein, Patrick C.
    de Boer, Anthonius
    Tan, Hanno L.
    EUROPACE, 2022, 24 (04): : 630 - 638
  • [3] Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries
    Eroglu, Talip E.
    Mohr, Grimur H.
    Blom, Marieke T.
    Verkerk, Arie O.
    Souverein, Patrick C.
    Torp-Pedersen, Christian
    Folke, Fredrik
    Wissenberg, Mads
    van den Brink, Lettine
    Davis, Richard P.
    de Boer, Anthonius
    Gislason, Gunnar H.
    Tan, Hanno L.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (06) : 347 - 355
  • [4] Factors associated with out-of-hospital cardiac arrest with pulseless electric activity: A population-based study
    Ko, Dennis T.
    Qiu, Feng
    Koh, Maria
    Dorian, Paul
    Cheskes, Sheldon
    Austin, Peter C.
    Scales, Damon C.
    Wijeysundera, Harindra C.
    Verbeek, P. Richard
    Drennan, Ian
    Ng, Tiffany
    Tu, Jack V.
    Morrison, Laurie J.
    AMERICAN HEART JOURNAL, 2016, 177 : 129 - 137
  • [5] Pediatric out-of-hospital cardiac arrest in Korea: A nationwide population-based study
    Park, Chang Bae
    Shin, Sang Do
    Suh, Gil Joon
    Ahn, Ki Ok
    Cha, Won Chul
    Song, Kyoung Jun
    Kim, Soo Jin
    Lee, Eui Jung
    Ong, Marcus Eng Hock
    RESUSCITATION, 2010, 81 (05) : 512 - 517
  • [6] Out-of-hospital cardiac arrest associated with venous thromboembolism-a Swedish population-based cohort study
    Bendz, Emma
    Oksanen, Anna
    Larsson, Susanna
    Ohm, Joel
    Djarv, Therese
    Bruzelius, Maria
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 23 (03) : 968 - 977
  • [7] Epidemiology, Risk Factors, and Outcomes of Out-of-Hospital Cardiac Arrest Caused by Stroke A Population-Based Study
    Fukuda, Tatsuma
    Ohashi-Fukuda, Naoko
    Kondo, Yutaka
    Sera, Toshiki
    Doi, Kent
    Yahagi, Naoki
    MEDICINE, 2016, 95 (14)
  • [8] Health care utilization prior to out-of-hospital cardiac arrest: A population-based study
    Shuvy, Mony
    Koh, Maria
    Qiu, Feng
    Brooks, Steven C.
    Chan, Timothy C. Y.
    Cheskes, Sheldon
    Dorian, Paul
    Geri, Guillaume
    Lin, Steve
    Scales, Damon C.
    Ko, Dennis T.
    RESUSCITATION, 2019, 141 : 158 - 165
  • [9] Out-of-hospital cardiac arrest in the elderly: A large-scale population-based study
    Libungan, Berglind
    Lindqvist, Jonny
    Stromsoe, Anneli
    Nordberg, Per
    Hollenberg, Jacob
    Albertsson, Per
    Karlsson, Thomas
    Herlitz, Johan
    RESUSCITATION, 2015, 94 : 28 - 32
  • [10] Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest
    Weeke, P.
    Jensen, A.
    Folke, F.
    Gislason, G. H.
    Olesen, J. B.
    Fosbol, E. L.
    Wissenberg, M.
    Lippert, F. K.
    Christensen, E. F.
    Nielsen, S. L.
    Holm, E.
    Kanters, J. K.
    Poulsen, H. E.
    Kober, L.
    Torp-Pedersen, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) : 490 - 497